Veeda Lifesciences majority stake sale at $300-400 million
The move
Veeda Lifesciences has relaunched a process to sell a majority stake at a $300-400 million valuation, Mint reported on 7 October 2026. The transaction could involve a stake of 51% and later lead to a full sale, according to a person familiar with the matter.
The process has approached private equity firms and strategic buyers. It is expected to include primary and secondary share sales, with existing investors including CX Partners expected to make a complete exit. The company has engaged JP Morgan as an advisor.
What Veeda Lifesciences does
Founded in 2004 by Apurva Shah and Binoy Gardi, Veeda Lifesciences provides services to biotech and pharmaceutical companies across drug development. Its work spans pre-clinical research, clinical pharmacology, clinical trials, clinical bioanalysis, biologics, chemistry and biology.
The company operates through four strategic business units, with activities in India and Europe. It also supports drug-development pipelines through real-world data capabilities on an AI platform.
Newsletter
The corridor, every morning.
Funding rounds and cross-border capital moves, one email, five minutes.
Veeda’s operations include patient-based clinical trials in India, clinical trials in Europe, biopharma services in Bengaluru and preclinical testing in Karnataka.
VCRL acquired Heads, a contract research organisation specialising in haemato-oncology trials across 25 locations in Europe, North America and the Asia Pacific region. If the current deal goes through, it would give the company a boost to fund expansion plans and expand its distribution network.
What the process includes
“The deal will entail a majority stake sale - that could be in the range of 51% and later result in a full sale. Both private equity firms and strategics have been tapped as part of the process,” one person familiar with the matter said.
More in Market Move
